BIO-RAD LABORATORIES-A (BIO) Stock Analyst Ratings
USA - NYSE:BIO - US0905722072 - Common Stock
310.96 USD
-0.47 (-0.15%)
310.96 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 76% to BIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 317.22. This target is 2.01% above the current price.
BIO was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about BIO.
In the previous month the buy percentage consensus was at a similar level.
BIO was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-30 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-30 | Citigroup | Maintains | Buy -> Buy |
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-01 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-09 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-02 | Citigroup | Maintains | Buy -> Buy |
| 2025-04-17 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-12 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-01-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-12-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-31 | Citigroup | Maintains | Buy -> Buy |
| 2024-10-01 | Citigroup | Upgrade | Neutral -> Buy |
| 2024-08-27 | Wells Fargo | Initiate | Equal-Weight |
| 2024-08-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-08-02 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-05-08 | UBS | Maintains | Buy -> Buy |
| 2024-04-03 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-02-16 | UBS | Maintains | Buy -> Buy |
| 2024-02-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-12-07 | UBS | Initiate | Buy |
| 2023-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023-08-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-04 | Credit Suisse | Maintains | Outperform -> Outperform |
| 2023-06-16 | Wells Fargo | Initiate | Overweight |
| 2023-05-08 | RBC Capital | Maintains | Outperform |
| 2023-05-08 | Citigroup | Maintains | Buy |
BIO-RAD LABORATORIES-A / BIO FAQ
Can you provide the average price target for BIO-RAD LABORATORIES-A stock?
10 analysts have analysed BIO and the average price target is 317.22 USD. This implies a price increase of 2.01% is expected in the next year compared to the current price of 310.96.
What is the consensus rating for BIO stock?
The consensus rating for BIO-RAD LABORATORIES-A (BIO) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for BIO stock?
The number of analysts covering BIO-RAD LABORATORIES-A (BIO) is 10.